Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912534 · ClinicalTrials.gov registry record · Phase 2
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
A Phase 2 study, sponsored by Carelon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 211
- Enrollment target
NCT01912534 is a Phase 2 study that has completed, run by Carelon Research. The registered enrollment target is 211 participants.
The verdict
NCT01912534, a Phase 2 study, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 211 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.
Interventions
- DRUG Placebo
- DRUG Valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01912534
The ClinicalTrials.gov registry entry for NCT01912534 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01912534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01912534 about?
NCT01912534 is a clinical study titled "Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM". The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.
What is the current status of trial NCT01912534?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2014-03. Estimated completion is 2019-07.
What interventions are being tested in trial NCT01912534?
The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG).
Who is sponsoring clinical trial NCT01912534?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.